[ SCENARIO · FREE · DETERMINISTIC ]
A PPQ Batch Out of Trend
A tablet has been transferred to a new site. The second process performance qualification batch passes every specification but misses the protocol’s own consistency criterion. Decide what the result means, where the explanation lives, and whether the process is ready for market.
What a scenario is not
A scenario is a judgment exercise, not an assessment and not a compliance verdict. Finishing it evidences that you worked through it — nothing more — and the dimensions it scores are SPEQ’s, not any regulator’s.
A medicine is being made at a new factory for the first time. One of the trial batches came out noticeably different from the others, even though it still passed its tests. You decide whether that matters, and whether the new factory is ready to supply patients.
Process performance qualification (PPQ) runs commercial-scale batches under a pre-approved protocol to show the process is reproducible. FDA’s 2011 process validation guidance asks the protocol to define its statistical methods and how deviations and nonconforming data are handled, and it states that PPQ must be completed successfully before commercial distribution. EU GMP Annex 15 adds that results failing pre-defined acceptance criteria are recorded as deviations and fully investigated.
A technology transfer is a transfer of knowledge, not of documents. When a receiving site’s PPQ drifts, the cause is usually something the sending site knew and never wrote down, and the launch date pushes in the direction of not finding it.
You are the technology-transfer engineer at the receiving site. The protocol calls for three consecutive commercial-scale batches. Batch 1 matched the sending site closely.
Batch 2 passes every release specification. Its mean dissolution at the specified time point is 86%, against 94% for batch 1 and a sending-site history of 92–97%. The protocol’s pre-defined criterion for inter-batch consistency in dissolution is not met. Each choice changes what you can still do.
The batch 2 results are in. Production is ready to start batch 3 tomorrow, and launch planning assumes the PPQ report is approved this month.
This is a judgment exercise, not a quiz: your choices change the situation. It is scored across protocol · investigation · knowledge · decision — the same dimensions an inspector effectively weighs when they follow the thread of a real deviation. There is no compliance verdict here; the debriefs explain consequences.
WHAT THE CORRECT PATH RESTS ON
The primary sources behind the debriefs. The authoritative text lives at each official source.
- FDA guidance — Process Validation: General Principles and Practices (January 2011, Rev. 1), §IV.C and §V ↗
- EU GMP Annex 15 — Qualification and Validation (2015), §2.7–2.8 and §5.10–5.14 ↗
- ICH Q10 — Pharmaceutical Quality System, §3.1.2 technology transfer ↗
- 21 CFR 211.100 — written procedures; deviations recorded and justified ↗
Finishing this exercise is recorded. What it evidences — and the things it does not — is set out against the published standard.
What this evidences →DO IT FOR REAL
- HOW-TO GUIDEHow to Perform Process Validation →Plan the PPQ the scenario turned on, with its criteria fixed before the data.
- TEMPLATEProcess Validation (PPQ) Protocol →Write the protocol whose inter-batch criterion decided the case.
- HOW-TO GUIDEHow to Perform a Technology Transfer →Move the process knowledge the receiving site was missing.
KEEP PRACTISING
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account